Afinum has invested in ProJect Pharmaceutics, enhancing its portfolio of founder-led healthcare businesses and positioning the company for accelerated growth in the biopharmaceutical services sector.

Information on the Target

Afinum has made a strategic investment in ProJect Pharmaceutics GmbH, a leading specialist in formulation development for biologics and complex small molecules, with a particular focus on antibody-drug conjugates (ADCs). This investment marks the eleventh and final platform investment for the Afinum 9 fund, showcasing Afinum's dedication to supporting exceptional, founder-led enterprises in the healthcare sector. The founders, Dr. Andreas Schütz and Mr. Hellerbrand, will remain as significant co-investors, reinforcing their commitment to guiding ProJect Pharmaceutics through its next growth phase.

ProJect Pharmaceutics is distinguished as a premier formulation development partner within the biopharma services sector. The company integrates extensive scientific knowledge with proprietary methodologies to address complex biologics and sophisticated modalities, particularly in ADCs. With a proven history of overcoming significant challenges in drug development through a technology-driven approach, ProJect Pharmaceutics has established reliable, long-term partnerships with a roster of esteemed global biopharma and innovative biotechnology firms.

Industry Overview in Germany

The biopharmaceutical industry in Germany has experienced substantial growth, bolstered by a robust research and development ecosystem supported by universities, research institutions, and a thriving start-up culture. The country is known for